SEASON South East Asian Study Of Novel Genotypes in Hepatitis C Infection: Pegylated-interferon and ribavirin therapy (PEGATRON REDIPEN combination therapy (PEG-Intron(R) REDIPEN Plus REBETOL(R))) in treatment naive patients With genotypes 1, 6, 7, 8, 9: A comparison of race and genotype on treatment outcome.

Trial Profile

SEASON South East Asian Study Of Novel Genotypes in Hepatitis C Infection: Pegylated-interferon and ribavirin therapy (PEGATRON REDIPEN combination therapy (PEG-Intron(R) REDIPEN Plus REBETOL(R))) in treatment naive patients With genotypes 1, 6, 7, 8, 9: A comparison of race and genotype on treatment outcome.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2015

At a glance

  • Drugs Peginterferon alfa-2b/ribavirin (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms SEASON
  • Sponsors Schering-Plough
  • Most Recent Events

    • 12 Jan 2010 Actual end date (Dec 2007) and actual noumber of patients (121) added as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 26 Mar 2008 The expected completion date for this trial is now 1 Dec 2007, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top